Locally Advanced Thyroid Cancer with Gross Extrathyroidal Extension (gETE)

Gross extrathyroidal extension (ETE):
- Is defined as direct tumor extension beyond the thyroid capsule into perithyroidal structures:
  - Identified clinically, on imaging, or on gross pathology:
    - This is the defining feature of locally advanced thyroid cancer
- It must be distinguished from microscopic (minimal) ETE (mETE):
  - Which is detected only histologically and, because of poor interobserver reproducibility (kappa ≈ 0.14) and negligible independent prognostic weight:
    - Was removed from AJCC 8th edition T-staging in 2017
  - Only gross ETE (gETE) now drives T-category and stage
Management is stratified by which structure is involved:
- Strap muscles vs. recurrent laryngeal nerve (RLN), trachea, larynx, esophagus vs. prevertebral fascia / great vessels:
  - With the central principle that complete gross resection with acceptable morbidity, followed by risk-adapted RAI and / or EBRT:
    - Offers the best locoregional control
Definitions and classification of ETE
Microscopic (minimal / minor) ETE (mETE):
- Tumor extension into immediate perithyroidal soft tissue or skeletal muscle:
  - Seen only on histology:
    - Not appreciated clinically or grossly
- Associated with a 3% to 9% recurrence risk:
  - With no consistent independent effect on disease-specific (DSS) or overall survival (OS)
Gross (extensive) ETE:
- Macroscopic invasion evident at surgery, on preoperative imaging, or on gross specimen exam:
  - Into strap muscles (T3b) or into subcutaneous soft tissue, larynx, trachea, esophagus, RLN (T4a), or prevertebral fascia / carotid / mediastinal vessels (T4b)
- Recurrence risk of 23% to 40%
- Disease-specific mortality of 23% to 52%
- The following Kaplan-Meier curves illustrate the sharp prognostic divergence:
  - Recurrence-free survival for mETE overlaps with no ETE (both near 100%), whereas gETE falls to roughly 35%

Adverse Outcome Based on the Degree of Extrathyroidal Extension

Epidemiology:
- ETE is present in roughly:
  - 10% to 15% of thyroid cancers at presentation:
    - Up to ~ 23.5% of papillary carcinomas in some pathologic series:
      - Most commonly involving the strap muscles
- Frank aerodigestive-tract invasion is less common:
  - Tracheal invasion occurs in an estimated:
    - 1% to 8% of thyroid carcinomas
  - RLN is involved in:
    - 33% to 61% of the subset of tumors classified as “invasive”
  - Overall, roughly 10% to 15% of DTC patients have locoregionally advanced disease:
    - Carrying substantially higher recurrence and mortality risk
Prognosis:
- Gross ETE (gETE):
  - Is an independent predictor of reduced disease-specific survival (DSS), higher local recurrence, and greater risk of nodal and distant metastasis
- In a SEER cohort of > 107,000 patients:
  - Cancer-specific mortality rates per 1,000 person-years rose stepwise:
    - 1.4 (thyroid-confined)
    - 5.1 (mETE)
    - 29.7 (gETE)
- Among invaded structures, tracheal invasion carries particular weight:
  - In one T4 DTC series it was the only factor significantly associated with recurrence, and airway obstruction from local spread accounts for a substantial share of DTC deaths:
    - Coexisting macroscopic extranodal extension further worsens outcomes:
      - With unresectable macroscopic ENE dropping 5-year DSS to ~ 82%
Staging (AJCC 8th edition):
- The T-category is anchored to the depth of gross ETE, and staging is heavily age-dependent (cutoff 55 years):
  - Below is the NCCN reproduction of the AJCC 8th edition TNM definitions for differentiated (and anaplastic) carcinoma

In patients < 55 years, any T with M0 is Stage I regardless of ETE. For anaplastic carcinoma, all disease is Stage IV (IVA /IVB / IVC), with the same T definitions. Note gETE also mandates total thyroidectomy and excludes a patient from active surveillance.

Management by structure involved:
- Surgery is the mainstay:
  - The goal is complete gross tumor removal (R0 / R1) balanced against functional morbidity:
    - Followed by risk-adapted adjuvant therapy
- A multidisciplinary team at a high-volume center:
  - Is recommended for bulky or viscerally invasive disease
- The overall airway / aerodigestive management framework hinges on:
- Whether invasion is:
  - Extraluminal:
    - Amenable to shave excision versus
  - Intraluminal:
    - Requiring formal resection

Algorithm for the management of locally advanced thyroid cancer.

Strap muscles (T3b):
- En bloc resection of the involved strap muscle with the thyroid:
  - This is well tolerated and does not compromise function
Recurrent laryngeal nerve (T4a):
- Management is dictated by preoperative vocal cord function and the extent of invasion:
  - Functioning nerve with tumor adherent /encasing but mobile cords:
    - Attempt preservation:
      - Shave / partial-layer resection to remove all gross disease while keeping neural continuity, followed by adjuvant therapy
      - Preserving a functioning nerve, even at the cost of microscopic residual,, does not worsen survival
  - Nonfunctioning nerve (preoperative paralysis) and / or complete encasement:
    - Resection of the involved segment is appropriate:
      - Ideally with immediate reconstruction (direct / end-to-end anastomosis, ansa cervicalis–to–RLN anastomosis, or nerve grafting) to restore phonatory and swallowing function
      - Keep in mind contralateral nerve, want to avoid tracheostomy
    - Intraoperative nerve monitoring (NIM) and staged contralateral surgery help avoid bilateral paralysis:
      - If signal is lost on the first side during planned total thyroidectomy, defer the contralateral lobe
- The following decision algorithm summarizes the RLN approach based on cord mobility and neural continuity:

Trachea (T4a):
- Extent of resection follows depth of invasion:
  - Shin classification
- Superficial invasion not penetrating perichondrium / cartilage:
  - Tangential shave excision achieves local control up to ~ 95%:
    - Though positive-margin and recurrence rates are higher:
      - So adjuvant therapy is typically added
- Intraluminal invasion or significant cartilage involvement:
  - Circumferential sleeve resection with end-to-end anastomosis:
    - Feasible for defects < ~ 5 cm / up to ~ half circumference)
  - Window resection with flap reconstruction is preferred for durable local control
  - Systematic review of 656 patients undergoing (crico)tracheal resection reported ~ 2% perioperative mortality, ~ 27% complications (mainly RLN palsy), 4% permanent tracheostomy, and 5-year DSS of 75.8% to 90%
Larynx / esophagus (T4a):
- Partial-thickness (“shave”) resection of the esophageal muscular wall or partial laryngeal / tracheal windowing is preferred when the lumen / mucosa is not breached
- Transmural esophageal or full laryngeal involvement may require segmental esophageal resection with flap reconstruction, partial / total laryngectomy, or laryngopharyngectomy — reserved for highly selected cases
Prevertebral fascia / carotid / mediastinal vessels (T4b):
- Often unresectable or borderline resectable:
  - Options include cervical exenteration at expert centers in selected patients, or non-surgical management with EBRT ± systemic therapy when curative resection is not feasible or acceptable
Adjuvant therapy (RAI and EBRT):
- After surgery, the NCCN algorithm:
  - Branches on presence of gross residual disease, resectability, and RAI avidity
- For locoregionally invasive disease or rapid progression:
  - EBRT or systemic therapy is considered

RAI:
- Indicated for iodine-avid residual / high-risk disease and is preferred when uptake is present:
  - Many invasive tumors, however, are relatively iodine-refractory
EBRT:
- The 2025 ATA guidelines state that adjuvant EBRT may be considered in select DTC patients with high-risk features for locoregional progression:
  - Aggressive histology
  - gETE
  - Positive margins
  - Visceral / soft-tissue invasion:
    - Especially when future progression would not be salvageable surgically:
      - Weighing improved locoregional relapse-free survival against toxicity and absence of a demonstrated overall survival benefit
- EBRT ± concurrent chemotherapy:
  - Is also an option for gross residual or locally advanced unresectable disease
  - Retrospective and propensity-matched data show:
    - Improved locoregional control:
      - e.g., 10-year local failure-free survival 88% for EBRT+RAI vs. 72% RAI alone in pT4a PTC
      - LRR reduced from 51% to 8% after tracheal shave without consistent OS gain
- Typical adjuvant EBRT doses for non-anaplastic thyroid cancer are:
  - 60 to 66 Gy to microscopic disease / thyroid bed
  - 50 to 56 Gy to elective nodal regions
  - 66 to 70 Gy for gross / unresectable disease:
    - Delivered by IMRT
- For BRAF V600E–mutated anaplastic carcinoma:
  - Neoadjuvant dabrafenib / trametinib and multimodal EBRT / chemoradiation apply on separate ATC-specific algorithms
References:
- Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association Management Guidelines for Adult Patients With Differentiated Thyroid Cancer. Thyroid. 2025.
- Sessa L, De Crea C, Voloudakis N, et al. Single Institution Experience in the Management of Locally Advanced (pT4) Differentiated Thyroid Carcinomas. Ann Surg Oncol. 2024.
- Scognamiglio T. Aggressive follicular cell derived thyroid carcinoma: what do you need from the pathologist. Virchows Arch. 2026.
- Xu B, Ghossein RA. Crucial parameters in thyroid carcinoma reporting – challenges, controversies and clinical implications. Histopathology. 2018.
- Xu B, Ghossein RA. Crucial parameters in thyroid carcinoma reporting – challenges, controversies and clinical implications. Histopathology. 2018.
- Shindo ML, Caruana SM, Kandil E, et al. Management of invasive well-differentiated thyroid cancer: An American Head and Neck Society consensus statement. Head Neck. 2014.
- Li M, Tang Q, Yang X, et al. Application of modified spiral tracheoplasty in thyroid carcinoma with trachea invasion: a retrospective analysis of 15 cases. World J Surg Oncol. 2024.
- Laskar SG, Mohanty S, Sinha S, et al. Adjuvant External Beam Radiotherapy in Differentiated Thyroid Cancers: An Audit of Clinical Practice, Adapting to New Evidence. Head Neck. 2025.
- Yuan SS, Zhang XR, Yu XQ, et al. Prediction model for extrathyroidal extension in thyroid papillary carcinoma based on ultrasound radiomics. Sci Rep. 2025.
- Liu Z, Huang Y, Chen S, et al. Minimal Extrathyroidal Extension Affects the Prognosis of Differentiated Thyroid Cancer: Is There a Need for Change in the AJCC Classification System? PLoS One. 2019. 12.
- Liu Y, Zhang X, Liu J, et al. Prognostic significance of the extent of extranodal extension in patients with pN1b papillary thyroid carcinoma: a retrospective cohort study. Eur Arch Otorhinolaryngol. 2026.
- National Comprehensive Cancer Network. Thyroid Carcinoma. NCCN Clinical Practice Guidelines in Oncology. 2026.
- Perrier ND, Brierley JD, Tuttle RM. Differentiated and Anaplastic Thyroid Carcinoma: Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin. 2018.
- Patel R. Thyroid. In: Essential Cases in Head and Neck Oncology. 2022.
- Fundakowski CE, Hales NW, Agrawal N, et al. Surgical management of the recurrent laryngeal nerve in thyroidectomy: American Head and Neck Society Consensus Statement. Head Neck. 2018.
- Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014.
- Masuoka H, Miyauchi A. Intraoperative Management of the Recurrent Laryngeal Nerve Transected or Invaded by Thyroid Cancer. Front Endocrinol (Lausanne). 2022.
- Rai S, Agarwal M, Bansal K, et al. Intraoperative management of recurrent laryngeal nerve invasion in thyroid carcinoma: Oncologic and functional outcomes with a surgical decision algorithm. Eur Arch Otorhinolaryngol. 2026.
- Wang S, Li S, Yang X, et al. Surgical treatment for patients with papillary thyroid carcinoma invading the cervical trachea. Eur Arch Otorhinolaryngol. 2026.
- Piazza C, Lancini D, Tomasoni M, et al. Tracheal and Cricotracheal Resection With End-to-End Anastomosis for Locally Advanced Thyroid Cancer: A Systematic Review of the Literature on 656 Patients. Front Endocrinol (Lausanne). 2021.
- Mercader-Cidoncha E, Zaraín-Obrador L, Lasso JM, Simón-Adiego C. Surgical Resources in Advanced Thyroid Cancer Treatment With Aerodigestive Tract Invasion. Surg Oncol. 2023.
- Scharpf J, Tuttle M, Wong R, et al. Comprehensive management of recurrent thyroid cancer: An American Head and Neck Society consensus statement. Head Neck. 2016.
- Piazza C, Lancini D, Paderno A. Cervical Exenteration and Its Variants for Locally Advanced Thyroid Cancer: When, Why, and How? Curr Opin Otolaryngol Head Neck Surg. 2023.
- Kiess AP, Agrawal N, Brierley JD, et al. External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. Head Neck. 2016.
- Kawamoto T, Shikama N, Fukumori T, Hoshi M, Yamada T. Propensity score matching analysis of adjuvant external-beam radiotherapy for the treatment of papillary thyroid carcinoma with other organ invasions. Endocrine. 2023.
- Laskar SG, Mohanty S, Sinha S, et al. Adjuvant External Beam Radiotherapy in Differentiated Thyroid Cancers: An Audit of Clinical Practice, Adapting to New Evidence. Head Neck. 2025.